NASDAQ:GBT
Delisted
GLOBAL BLOOD THERAPEUTICS Stock News
$68.49
+0 (+0%)
At Close: Jan 27, 2023
GBT Establishes The GBT Foundation to Improve the Health and Well-being of Underserved Patient Communities Around the World
11:00am, Tuesday, 14'th Sep 2021
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced the launch of The GBT Foundation, a 501(c)(3) organization and source of
GBT Announces New Employment Inducement Grants
08:00am, Thursday, 09'th Sep 2021
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on September 1, 2021, the compensation committee of GBT's boa
GBT and Sickle Cell Disease Association of America to Host 10th Annual Sickle Cell Disease (SCD) Therapeutics Conference
05:05pm, Wednesday, 08'th Sep 2021
Centers for Medicare & Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure to deliver keynote Centers for Medicare & Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure to deliver ke
Global Blood's (GBT) NDA & sNDA for Oxbryta Get Priority Review
11:00am, Wednesday, 08'th Sep 2021
The FDA grants priority review to Global Blood's (GBT) sNDA for Oxbryta to treat SCD in children aged four to 11 years, as well as to its NDA for a pediatric weight-based formulation of the drug.
Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe
12:10pm, Monday, 30'th Aug 2021
Global Blood's (GBT) Oxbryta is approved for treating sickle cell disease. The drug has seen solid uptake since its launch.
Why Shares of Global Blood Therapeutics Are Soaring Today
01:26pm, Monday, 23'rd Aug 2021
The biotech company has only one drug, Oxbryta, on the market, to treat sickle cell disease. Its shares were up Monday after falling on Friday.
Global Blood Therapeutics: Attempting To Classify The Investment
03:43am, Saturday, 07'th Aug 2021
Global Blood Therapeutics: Attempting To Classify The Investment
Why Global Blood Therapeutics Is Rallying Today
01:18pm, Wednesday, 04'th Aug 2021
This heavily shorted biotech finally had some good news.
Global Blood's (GBT) Q2 Earnings Beat, Revenues Rise Y/Y
11:28am, Wednesday, 04'th Aug 2021
Global Blood (GBT) reports a narrower-than-expected loss in the second quarter of 2021 while its revenues also beat estimates.
Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q2 2021 Results - Earnings Call Transcript
11:16pm, Tuesday, 03'rd Aug 2021
Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q2 2021 Results - Earnings Call Transcript
Global Blood Therapeutics (GBT) Reports Q2 Loss, Tops Revenue Estimates
07:04pm, Tuesday, 03'rd Aug 2021
Global Blood (GBT) delivered earnings and revenue surprises of 4.27% and 8.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
GBT Reports Second Quarter 2021 Financial Results
04:05pm, Tuesday, 03'rd Aug 2021
Achieved Oxbryta ® (voxelotor) net revenues of $47.6 million, an increase of 51% year-over-year
GBT Provides Regulatory and Pipeline Updates in Sickle Cell Disease (SCD)
07:00am, Thursday, 22'nd Jul 2021
Submits Supplemental New Drug Application to the U.S. FDA for Oxbryta ® (voxelotor) in Children with SCD Ages 4 to 11
GBT Announces New Employment Inducement Grants
08:00am, Friday, 09'th Jul 2021
SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on July 1, 2021, the compensation committee of GBT's board of
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation
